NAPRC Accreditation Linked to Increased Rectal Cancer Patient Volume

The Evolving Landscape of Specialized Rectal Cancer Care

Colorectal cancer remains one of the most prevalent malignancies in the United States, with the number of survivors projected to exceed 22 million by 2035 [1]. Despite advancements in early detection and treatment, significant disparities persist in the delivery of high-quality surgical care, particularly for vulnerable populations [2]. Managing rectal adenocarcinoma requires a complex, multidisciplinary approach to navigate the risks of postoperative complications, such as infections and wound healing disorders, which are further exacerbated by comorbidities like diabetes [3]. While adherence to guideline-concordant care is known to improve survival outcomes, the institutional burden of maintaining these rigorous standards often requires extensive staffing and infrastructure [2]. To understand whether this heavy institutional investment yields tangible shifts in care delivery, researchers recently evaluated how formal accreditation programs influence patient volumes and procedural patterns in this high-stakes clinical environment.

Analyzing the Impact of Multidisciplinary Standards

The researchers evaluated whether National Accreditation Program for Rectal Cancer (NAPRC) accreditation is associated with changes in rectal cancer patient volume, stage-specific procedural volumes, and care fragmentation. This accreditation process requires institutions to demonstrate strict adherence to multidisciplinary rectal cancer care standards, undergo regular external audits, and ensure clinical staff complete specialized training. For practicing clinicians, these standards represent a formalized commitment to integrated care pathways involving surgery, medical oncology, pathology, and radiology. The study population included adult patients diagnosed with primary rectal adenocarcinoma between 2010 and 2022, with data extracted from the National Cancer Database and analyzed between April and August 2025. To isolate the specific impact of the accreditation, the study utilized a quasi-experimental difference-in-differences design, a statistical method that compares changes in outcomes over time between a treatment group of accredited hospitals and a matched control group of nonaccredited facilities. The authors further refined their analysis using linear fixed-effects multivariable regression models. This statistical approach controls for time-invariant characteristics of hospitals, such as geographic location or baseline institutional resources, to isolate the effect of accreditation from other confounding variables. By employing these methodologies, the researchers sought to determine if the institutional investment required for NAPRC status translates into measurable shifts in patient volume and the continuity of oncologic care.

Institutional Growth and Procedural Trends

The researchers identified an initial pool of 1336 facilities accredited by the US Commission on Cancer. From this group, 80 hospitals achieved accreditation through the National Accreditation Program for Rectal Cancer, while 1256 never attained the designation. To ensure a rigorous comparison, the study utilized propensity score matching, a technique that pairs institutions with similar baseline characteristics to better isolate the effects of the accreditation itself. This yielded a final cohort of 316 US Commission on Cancer-accredited hospitals, consisting of the 80 accredited sites and 236 matched nonaccredited centers. The analysis found that accreditation was associated with a mean annual increase of 4.3 patients with rectal cancer per institution (beta = 4.29; 95% CI, 0.55 to 8.03; P = .03). Sensitivity analyses, which are secondary tests used to confirm the robustness of a primary finding, demonstrated that these volume increases began in the first year following accreditation. While the point estimates for volume increases were larger in subsequent years, these later estimates did not reach statistical significance. When examining the types of cases driving this growth, the researchers found that accreditation was associated with a significant increase in stage I procedural volume (beta = 1.01; 95% CI, 0.016 to 1.99; P = .05). In contrast, there was no associated change in surgical volume for stage II or stage III disease. For the practicing clinician, these data indicate that institutional growth following accreditation is primarily driven by an influx of early-stage cases, potentially reflecting increased referrals for localized, curative-intent procedures.

Preserving Continuity of Care

A primary concern in the centralization of specialized oncologic services is the potential for care fragmentation, which can disrupt the multidisciplinary coordination essential for rectal cancer management. In this study, the researchers defined care fragmentation as any case in which the diagnosis and first-course treatment, or the formal decision not to treat, were not completed at the reporting Commission on Cancer-accredited facility. For the practicing clinician, this definition captures the critical window between initial detection and the commencement of therapy, a period where patient handoffs between disparate institutions can lead to delays in staging or deviations from standardized treatment protocols. The analysis of 316 hospitals demonstrated that the institutional growth driven by National Accreditation Program for Rectal Cancer standards did not come at the expense of integrated care. The researchers found that no significant changes in care fragmentation were observed following accreditation. This suggests that these institutions successfully absorbed increased patient volumes while maintaining the continuity of the diagnostic and therapeutic pathway. This stability is highly relevant for hospital leadership and oncology teams, as it indicates that the rigorous infrastructure required for accreditation, including multidisciplinary tumor boards and specialized administrative support, effectively anchors the patient within a single system from the point of diagnosis through the completion of their primary treatment plan.

References

1. Wagle NS, Nogueira L, Devasia TP, et al. Cancer treatment and survivorship statistics, 2025. CA A Cancer Journal for Clinicians. 2025. doi:10.3322/caac.70011

2. Chan K, Palis BE, Cotler JH, et al. Social Vulnerability and Receipt of Guideline-Concordant Care among Patients with Colorectal Cancer.. Journal of the American College of Surgeons. 2024. doi:10.1097/xcs.0000000000001193

3. Zhang X, Hou A, Cao J, et al. Association of Diabetes Mellitus With Postoperative Complications and Mortality After Non-Cardiac Surgery: A Meta-Analysis and Systematic Review. Frontiers in Endocrinology. 2022. doi:10.3389/fendo.2022.841256